Clinical Trial Update: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). [Phase 2]

View source ↗

Summary

Phase II clinical trial update for a time-limited combination therapy (pirtobrutinib, venetoclax, obinutuzumab) in recurrent Chronic Lymphocytic Leukemia/Small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL) | Phase 2 | Status: RECRUITING